REPLY: We thank Bela Denes and Peter Gardiner from Blue-Earth Diagnostics, Inc., for their
interest in our case series (1) and their relevant letter. BlueEarth Diagnostics, Inc., showed …

The well-recognized limitations of conventional imaging with CT, MRI, and 99mTc-
methylene diphosphonate bone scans have contributed to a revolution in PET imaging of …

First, a specific 18F-choline acquisition protocol would improve the detection of recurrent
prostate cancer, either for prostatic fossae or for lymph nodes. PET acquisition at only 20 min …

Recently, in the European Journal of Nuclear Medicine and Molecular Imaging, a paper
entitled:“68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical …

Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands are a new class of
prostate cancer theranostic agents. 18F-rhPSMA-7 offers the advantages of 18F labeling …

1262 Background: Prostate-specific membrane antigen (PSMA)-targeted PET imaging has
changed the management of patients with prostate cancer (PCa). F18-PSMA is a novel …

[en] A rise in prostate-specific antigen serum level (PSA) is an increasing issue, which
occurs in more than one third of the patients who underwent radical prostatectomy. Thus …

We report a case of a 59-year-old man with prostate adenocarcinoma, Gleason score 9 after
prostatectomy and adjuvant radiotherapy. The patient showed biochemical recurrence. On …

1343 Background: 68Ga PSMA PET/CT is known to impact management in patients with
prostate cancer. 18F PSMA 1007 is a relatively novel tracer which seems to have …

This was a head-to-head comparison between 68 Ga-labeled prostate-specific membrane
antigen (PSMA)-11 and 18 F-fluciclovine PET/CT in a series of 10 patients with prostate …